Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 203

1.

Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.

O'Brien S, Hillmen P, Coutre S, Barr PM, Fraser G, Tedeschi A, Burger JA, Dilhuydy MS, Hess G, Moreno C, Cramer P, Liu E, Chang S, Vermeulen J, Styles L, Howes A, James DF, Patel K, Graef T, Valentino R.

Clin Lymphoma Myeloma Leuk. 2018 Jun 28. pii: S2152-2650(18)30265-9. doi: 10.1016/j.clml.2018.06.016. [Epub ahead of print]

2.

Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As2O3) and all-trans retinoic acid (ATRA).

Jain P, Konoplev S, Benjamini O, Romagura J, Burger JA.

Blood Res. 2018 Jun;53(2):169-172. doi: 10.5045/br.2018.53.2.169. Epub 2018 Jun 25. No abstract available.

3.

Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies.

Peled A, Klein S, Beider K, Burger JA, Abraham M.

Cytokine. 2018 Sep;109:11-16. doi: 10.1016/j.cyto.2018.02.020.

PMID:
29903571
4.

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.

Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, Burger JA, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James D, Kipps TJ, Ghia P.

Haematologica. 2018 Jun 7. pii: haematol.2018.192328. doi: 10.3324/haematol.2018.192328. [Epub ahead of print]

5.

Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy.

Burger JA, O'Brien S.

Nat Rev Clin Oncol. 2018 Aug;15(8):510-527. doi: 10.1038/s41571-018-0037-8. Review.

PMID:
29777163
6.

Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies.

Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WG.

Leukemia. 2018 Apr 17. doi: 10.1038/s41375-018-0132-y. [Epub ahead of print]

PMID:
29769624
7.

New pieces in the BTKi resistance puzzle.

Burger JA.

Blood. 2018 May 3;131(18):1995-1996. doi: 10.1182/blood-2018-03-837849. No abstract available.

PMID:
29724714
8.

Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy.

Schliffke S, Sivina M, Kim E, von Wenserski L, Thiele B, Akyüz N, Falker-Gieske C, Statovci D, Oberle A, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Jain N, Estrov Z, Ferrajoli A, Wierda W, Keating M, Burger JA, Binder M.

Oncoimmunology. 2018 Jan 15;7(4):e1417720. doi: 10.1080/2162402X.2017.1417720. eCollection 2018.

PMID:
29632735
9.

Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia.

Strati P, Ferrajoli A, Wierda WG, Jain N, Thompson PA, O'Brien SM, Rezvani K, Kantarjian HM, Burger JA, Hinojosa CO, Keating MJ, Estrov Z.

Leukemia. 2018 Feb 20. doi: 10.1038/s41375-018-0059-3. [Epub ahead of print] No abstract available.

PMID:
29479067
10.

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.

O'Brien S, Furman RR, Coutre S, Flinn IW, Burger JA, Blum K, Sharman J, Wierda W, Jones J, Zhao W, Heerema NA, Johnson AJ, Luan Y, James DF, Chu AD, Byrd JC.

Blood. 2018 Apr 26;131(17):1910-1919. doi: 10.1182/blood-2017-10-810044. Epub 2018 Feb 2.

11.

Immunogenicity in Rabbits of HIV-1 SOSIP Trimers from Clades A, B, and C, Given Individually, Sequentially, or in Combination.

Torrents de la Peña A, de Taeye SW, Sliepen K, LaBranche CC, Burger JA, Schermer EE, Montefiori DC, Moore JP, Klasse PJ, Sanders RW.

J Virol. 2018 Mar 28;92(8). pii: e01957-17. doi: 10.1128/JVI.01957-17. Print 2018 Apr 15.

12.

Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide.

Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Wierda WG, Futreal PA, Ferrajoli A.

Blood. 2018 Apr 19;131(16):1820-1832. doi: 10.1182/blood-2017-11-817296. Epub 2018 Jan 22.

PMID:
29358183
13.

Targeting B cell receptor signalling in cancer: preclinical and clinical advances.

Burger JA, Wiestner A.

Nat Rev Cancer. 2018 Mar;18(3):148-167. doi: 10.1038/nrc.2017.121. Epub 2018 Jan 19. Review.

PMID:
29348577
14.

Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.

Tissino E, Benedetti D, Herman SEM, Ten Hacken E, Ahn IE, Chaffee KG, Rossi FM, Dal Bo M, Bulian P, Bomben R, Bayer E, Härzschel A, Gutjahr JC, Postorino M, Santinelli E, Ayed A, Zaja F, Chiarenza A, Pozzato G, Chigaev A, Sklar LA, Burger JA, Ferrajoli A, Shanafelt TD, Wiestner A, Del Poeta G, Hartmann TN, Gattei V, Zucchetto A.

J Exp Med. 2018 Feb 5;215(2):681-697. doi: 10.1084/jem.20171288. Epub 2018 Jan 4.

15.

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.

Landau DA, Sun C, Rosebrock D, Herman SEM, Fein J, Sivina M, Underbayev C, Liu D, Hoellenriegel J, Ravichandran S, Farooqui MZH, Zhang W, Cibulskis C, Zviran A, Neuberg DS, Livitz D, Bozic I, Leshchiner I, Getz G, Burger JA, Wiestner A, Wu CJ.

Nat Commun. 2017 Dec 19;8(1):2185. doi: 10.1038/s41467-017-02329-y.

16.

Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers.

de Taeye SW, de la Peña AT, Vecchione A, Scutigliani E, Sliepen K, Burger JA, van der Woude P, Schorcht A, Schermer EE, van Gils MJ, LaBranche CC, Montefiori DC, Wilson IA, Moore JP, Ward AB, Sanders RW.

J Biol Chem. 2018 Feb 2;293(5):1688-1701. doi: 10.1074/jbc.RA117.000709. Epub 2017 Dec 8.

17.

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies.

Flinn IW, O'Brien S, Kahl B, Patel M, Oki Y, Foss FF, Porcu P, Jones J, Burger JA, Jain N, Kelly VM, Allen K, Douglas M, Sweeney J, Kelly P, Horwitz S.

Blood. 2018 Feb 22;131(8):877-887. doi: 10.1182/blood-2017-05-786566. Epub 2017 Nov 30.

PMID:
29191916
18.

Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).

Thompson PA, Burger JA.

Expert Opin Investig Drugs. 2018 Jan;27(1):31-42. doi: 10.1080/13543784.2018.1404027. Epub 2017 Nov 15. Review.

PMID:
29125406
19.

Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.

Kondo K, Shaim H, Thompson PA, Burger JA, Keating M, Estrov Z, Harris D, Kim E, Ferrajoli A, Daher M, Basar R, Muftuoglu M, Imahashi N, Alsuliman A, Sobieski C, Gokdemir E, Wierda W, Jain N, Liu E, Shpall EJ, Rezvani K.

Leukemia. 2018 Apr;32(4):960-970. doi: 10.1038/leu.2017.304. Epub 2017 Oct 3.

PMID:
28972595
20.

Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization.

Torrents de la Peña A, Julien JP, de Taeye SW, Garces F, Guttman M, Ozorowski G, Pritchard LK, Behrens AJ, Go EP, Burger JA, Schermer EE, Sliepen K, Ketas TJ, Pugach P, Yasmeen A, Cottrell CA, Torres JL, Vavourakis CD, van Gils MJ, LaBranche C, Montefiori DC, Desaire H, Crispin M, Klasse PJ, Lee KK, Moore JP, Ward AB, Wilson IA, Sanders RW.

Cell Rep. 2017 Aug 22;20(8):1805-1817. doi: 10.1016/j.celrep.2017.07.077.

21.

Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia.

Strati P, Keating MJ, Burger JA, O'Brien SM, Wierda WG, Estrov Z, Zacharian G, Ferrajoli A.

Haematologica. 2017 Dec;102(12):e494-e496. doi: 10.3324/haematol.2017.171561. Epub 2017 Aug 10. No abstract available.

22.

Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia.

Hacken ET, Gounari M, Back JW, Shimanovskaya E, Scarfò L, Kim E, Burks J, Ponzoni M, Ramirez GA, Wierda WG, Estrov Z, Keating MJ, Ferrajoli A, Stamatopoulos K, Ghia P, Burger JA.

Haematologica. 2017 Oct;102(10):e394-e396. doi: 10.3324/haematol.2017.169102. Epub 2017 Jul 27. No abstract available.

23.

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.

Brown JR, Moslehi J, O'Brien S, Ghia P, Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Kipps TJ, Coutre S, Dilhuydy MS, Cramer P, Tedeschi A, Jaeger U, Dreyling M, Byrd JC, Howes A, Todd M, Vermeulen J, James DF, Clow F, Styles L, Valentino R, Wildgust M, Mahler M, Burger JA.

Haematologica. 2017 Oct;102(10):1796-1805. doi: 10.3324/haematol.2017.171041. Epub 2017 Jul 27.

24.

CLL progression after one cycle of FCR: Richter's transformation versus EBV-associated lympho-proliferation.

Jain P, Burger JA, Khoury JD.

Am J Hematol. 2017 Oct;92(10):1113-1114. doi: 10.1002/ajh.24841. Epub 2017 Aug 10. No abstract available.

PMID:
28670739
25.

Tonic B-cell receptor signaling in diffuse large B-cell lymphoma.

Havranek O, Xu J, Köhrer S, Wang Z, Becker L, Comer JM, Henderson J, Ma W, Man Chun Ma J, Westin JR, Ghosh D, Shinners N, Sun L, Yi AF, Karri AR, Burger JA, Zal T, Davis RE.

Blood. 2017 Aug 24;130(8):995-1006. doi: 10.1182/blood-2016-10-747303. Epub 2017 Jun 23.

PMID:
28646116
26.

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.

Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre SE, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Thornton P, Caligaris-Cappio F, Delgado J, Montillo M, DeVos S, Moreno C, Pagel JM, Munir T, Burger JA, Chung D, Lin J, Gau L, Chang B, Cole G, Hsu E, James DF, Byrd JC.

Leukemia. 2018 Jan;32(1):83-91. doi: 10.1038/leu.2017.175. Epub 2017 Jun 8.

27.

Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.

Jones JA, Hillmen P, Coutre S, Tam C, Furman RR, Barr PM, Schuster SJ, Kipps TJ, Flinn IW, Jaeger U, Burger JA, Cheng M, Ninomoto J, James DF, Byrd JC, O'Brien SM.

Br J Haematol. 2017 Jul;178(2):286-291. doi: 10.1111/bjh.14660. Epub 2017 Apr 10.

28.

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.

Barr PM, Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Mulligan SP, Jaeger U, Furman RR, Cymbalista F, Montillo M, Dearden C, Robak T, Moreno C, Pagel JM, Burger JA, Suzuki S, Sukbuntherng J, Cole G, James DF, Byrd JC.

Blood. 2017 May 11;129(19):2612-2615. doi: 10.1182/blood-2016-12-737346. Epub 2017 Apr 3.

29.

Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.

Jain P, Thompson PA, Keating M, Estrov Z, Ferrajoli A, Jain N, Kantarjian H, Burger JA, O'Brien S, Wierda WG.

Cancer. 2017 Jun 15;123(12):2268-2273. doi: 10.1002/cncr.30596. Epub 2017 Feb 7.

30.

HSP90, a chaperone that can make you SYK.

Ten Hacken E, Burger JA.

Blood. 2017 Feb 2;129(5):542-544. doi: 10.1182/blood-2016-12-753152. No abstract available.

31.

Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib.

Burger JA, Li KW, Keating MJ, Sivina M, Amer AM, Garg N, Ferrajoli A, Huang X, Kantarjian H, Wierda WG, O'Brien S, Hellerstein MK, Turner SM, Emson CL, Chen SS, Yan XJ, Wodarz D, Chiorazzi N.

JCI Insight. 2017 Jan 26;2(2):e89904. doi: 10.1172/jci.insight.89904.

32.

Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.

Yin Q, Sivina M, Robins H, Yusko E, Vignali M, O'Brien S, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Burger JA.

J Immunol. 2017 Feb 15;198(4):1740-1747. doi: 10.4049/jimmunol.1601190. Epub 2017 Jan 11.

33.

Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Coutré SE, Furman RR, Flinn IW, Burger JA, Blum K, Sharman J, Jones J, Wierda W, Zhao W, Heerema NA, Johnson AJ, Tran A, Zhou C, Bilotti E, James DF, Byrd JC, O'Brien S.

Clin Cancer Res. 2017 Mar 1;23(5):1149-1155. doi: 10.1158/1078-0432.CCR-16-1431. Epub 2017 Jan 10.

34.

Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK.

Kim E, Hurtz C, Koehrer S, Wang Z, Balasubramanian S, Chang BY, Müschen M, Davis RE, Burger JA.

Blood. 2017 Mar 2;129(9):1155-1165. doi: 10.1182/blood-2016-06-722900. Epub 2016 Dec 28.

35.

Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia.

Jain P, Keating MJ, Wierda WG, Sivina M, Thompson PA, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien S, Burger JA.

Clin Cancer Res. 2017 May 1;23(9):2154-2158. doi: 10.1158/1078-0432.CCR-16-1948. Epub 2016 Oct 19.

36.

Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation.

Sivina M, Werner L, Rassenti L, Ferrajoli A, Wierda WG, Keating MJ, O'Brien S, Neuberg D, Kipps T, Burger JA.

Br J Haematol. 2018 Feb;180(4):597-600. doi: 10.1111/bjh.14398. Epub 2016 Oct 21. No abstract available.

PMID:
27766619
37.

Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs.

Mathur R, Sehgal L, Havranek O, Köhrer S, Khashab T, Jain N, Burger JA, Neelapu SS, Davis RE, Samaniego F.

Haematologica. 2017 Feb;102(2):373-380. doi: 10.3324/haematol.2016.144964. Epub 2016 Oct 14.

38.

The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.

Blunt MD, Koehrer S, Dobson RC, Larrayoz M, Wilmore S, Hayman A, Parnell J, Smith LD, Davies A, Johnson PWM, Conley PB, Pandey A, Strefford JC, Stevenson FK, Packham G, Forconi F, Coffey GP, Burger JA, Steele AJ.

Clin Cancer Res. 2017 May 1;23(9):2313-2324. doi: 10.1158/1078-0432.CCR-16-1662. Epub 2016 Oct 3.

39.

Long-term Effects of Rock Type on Appalachian Coal Mine Soil Properties.

Nash WL, Daniels WL, Haering KC, Burger JA, Zipper CE.

J Environ Qual. 2016 Sep;45(5):1597-1606.

PMID:
27695755
40.

A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.

Jain N, Balakrishnan K, Ferrajoli A, O'Brien SM, Burger JA, Kadia TM, Cortes JE, Ayres ML, Tambaro FP, Keating MJ, Gandhi V, Wierda WG.

Oncotarget. 2017 Mar 28;8(13):22104-22112. doi: 10.18632/oncotarget.12054.

41.

Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia.

Fiorcari S, Maffei R, Audrito V, Martinelli S, Ten Hacken E, Zucchini P, Grisendi G, Potenza L, Luppi M, Burger JA, Deaglio S, Marasca R.

Oncotarget. 2016 Oct 4;7(40):65968-65981. doi: 10.18632/oncotarget.11782.

42.

Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL.

Khouri IF, Sui D, Jabbour EJ, Samuels BI, Turturro F, Alatrash G, Anderlini P, Ahmed S, Oran B, Ciurea SO, Marin D, Olson A, Patel KK, Popat UR, Ledesma C, Kadia TM, Ferrajoli A, Burger JA, Jorgensen JL, Medeiros LJ, Bassett RL, Gulbis AM.

Bone Marrow Transplant. 2017 Jan;52(1):28-33. doi: 10.1038/bmt.2016.204. Epub 2016 Sep 5.

43.

Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia.

Ten Hacken E, Sivina M, Kim E, O'Brien S, Wierda WG, Ferrajoli A, Estrov Z, Keating MJ, Oellerich T, Scielzo C, Ghia P, Caligaris-Cappio F, Burger JA.

J Immunol. 2016 Sep 15;197(6):2522-31. doi: 10.4049/jimmunol.1600915. Epub 2016 Aug 17.

44.

Probability of N332 glycan occupancy on HIV-1 gp120 modulates sensitivity to broadly neutralizing antibodies.

van den Kerkhof TL, van Gils MJ, Boeser-Nunnink BD, Burger JA, Schuitemaker H, Sanders RW.

AIDS. 2016 Sep 10;30(14):2179-84. doi: 10.1097/QAD.0000000000001177.

PMID:
27258397
45.

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.

Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, Wang L, Stewart C, Fan J, Hoellenriegel J, Sivina M, Dubuc AM, Fraser C, Han Y, Li S, Livak KJ, Zou L, Wan Y, Konoplev S, Sougnez C, Brown JR, Abruzzo LV, Carter SL, Keating MJ, Davids MS, Wierda WG, Cibulskis K, Zenz T, Werner L, Dal Cin P, Kharchencko P, Neuberg D, Kantarjian H, Lander E, Gabriel S, O'Brien S, Letai A, Weitz DA, Nowak MA, Getz G, Wu CJ.

Nat Commun. 2016 May 20;7:11589. doi: 10.1038/ncomms11589.

46.

Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity.

Thompson PA, Stingo F, Keating MJ, Ferrajoli A, Burger JA, Wierda WG, Kadia TM, O'Brien SM.

Cancer. 2016 Aug 15;122(16):2505-11. doi: 10.1002/cncr.30069. Epub 2016 May 16.

47.

Discussion: Managing Risk When Using Idelalisib.

Coutre SE, Burger JA, Pagel JM.

Clin Adv Hematol Oncol. 2016 May;14(5 Suppl 8):13. No abstract available.

PMID:
27168205
48.

Targeted Agents for the Frontline Management of Chronic Lymphocytic Leukemia.

Burger JA.

Clin Adv Hematol Oncol. 2016 May;14(5 Suppl 8):7-12. Review. No abstract available.

PMID:
27168204
49.

Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia.

Brown JR, Harb WA, Hill BT, Gabrilove J, Sharman JP, Schreeder MT, Barr PM, Foran JM, Miller TP, Burger JA, Kelly KR, Mahadevan D, Ma S, Li Y, Pierce DW, Barnett E, Marine J, Miranda M, Azaryan A, Yu X, Nava-Parada P, Mei J, Kipps TJ.

Haematologica. 2016 Jul;101(7):e295-8. doi: 10.3324/haematol.2015.140806. Epub 2016 May 5. No abstract available.

50.

Ibrutinib for Chronic Lymphocytic Leukemia.

Burger JA, Styles L, Kipps TJ.

N Engl J Med. 2016 Apr 21;374(16):1594-5. doi: 10.1056/NEJMc1600328. No abstract available.

PMID:
27096594

Supplemental Content

Loading ...
Support Center